Quest Diagnostics Incorporated v. Elarja

District Court, D. Nevada·Decided June 13, 2022·No. 2:22-cv-00647·Unknown

Opinion

QUEST DIAGNOSTICS INCORPORATED, ) ) Plaintiff, ) Case No.: 2:22-cv-00647-GMN-EJY vs. ) ) ORDER ABDELRAHMAN ELARJA, ) ) Defendant. ) ) Pending before the Court is the Amended Motion for Preliminary Injunction, (ECF No. 12), filed by Plaintiff Quest Diagnostics, Incorporated (“Plaintiff” or “Quest”). Defendant Abdelrahman Elarja filed a Response, (ECF No. 19), to which Plaintiff filed a Reply, (ECF No. 21). For the reasons set forth below, Plaintiff’s Motion for Temporary Restraining Order is This action arises from Abdelrahman Elarja’s (“Defendant’s”) alleged misappropriation of trade secrets and breach of contract while employed at Quest Diagnostics, Inc. (See Verified Compl., ECF No. 1). Plaintiff alleges the following information. Defendant began working with Quest on April 23, 2018, as a Laboratory Supervisor. (Id. ¶ 8). Defendant’s responsibilities included performing advanced or specialized tests, confirming test results, checking and approving all specialized and problem reports for accuracy, and initiating quality control measures when needed. (Id. ¶ 9). Defendant, as part of his employment, entered into an Application Agreement, in which he agreed to “not use or disclose (directly or indirectly) any Confidential Information [. . .] at any time or in any manner, except as required in the course of employment with the Company.” (Id. ¶ 10); (see also Application Agreement, Ex. 1 to Verified Compl., ECF No. 1-1). Confidential Information, as defined by the Application Agreement, includes: information not generally known to the public, including but not limited to trade secrets, patient information, business plans, formulas, technical data, protocols, processes, computer software, customer names, pricing, test results, sales and marketing information and materials, financial information, client information and business methods, plans, policies and practices. If I am unsure whether or not information is confidential, I agree to speak with my manager before disclosing the information. (Application Agreement at 1). Defendant also entered into a Confidentiality Agreement, in which he also agreed not to disclose any Confidential Information. (Verified Compl. ¶ 12); (see also Confidentiality Agreement at 3, Ex. 2 to Verified Compl., ECF No. 1-2). On March 23, 2022, Quest’s Data Protection and Governance Department captured an email sent by Defendant from his work server email to his personal email address that included Confidential Information, including Quest’s Standard Operating Procedures (“SOPs”) and training guides. (Verified Compl. ¶ 19). Defendant’s supervisor, Remisola Ajayi, spoke with Defendant to determine why he sent confidential information to his personal account. (Id. ¶ 20). Defendant explained that he sent the information because “he liked to study.” (Id.). As a result of the alleged misappropriation, Quest opened an investigation and discovered that Defendant downloaded a cloud storage program on his work computer. (Id. ¶ 21). On April 2, 2021 and August 19, 2021, Defendant allegedly sent another work email to his personal account on that attached a patient’s test results. (Id. ¶ 22). Plaintiff believes these test results belonged to Defendant’s wife. (Id.). // // On June 8, 2021, Defendant allegedly sent a few emails from his work server email to his personal email concerning another clinical laboratory, Express Medical Labs. (Id. ¶ 23). The emails were titled with information unrelated to the actual emails. (Id.). For example, one email sent on June 8, 2021, included the subject line “lighthouse” but included talking points for Express Medical Labs. (Id.). Specifically, the email states: “Express medical labs strives for excellence in all facilities” and discusses testing and “feedback from experts.” (Id.). From January 9, 2022, to March 23, 2022, Defendant allegedly continued to misappropriate Quest’s SOPs by sending proprietary information to his personal account with misleading and mislabeled subject lines in an attempt to avoid scrutiny from Quest’s Data Protection and Governance Department. (Id. ¶ 27). For example, Defendant allegedly sent an email with the subject line, “Insurance” but attached Quest’s SOP on incident and injury reporting procedures. (Id.). Given Defendant’s prior history with Express Medical Labs, Plaintiff believes Defendant has shared Confidential Information with Express Medical Labs, in violation of the Application Agreement and Confidentiality Agreement. (Id. ¶ 32). As a result of Defendant’s multiple violations, Plaintiff terminated Defendant’s employment on March 29, 2022. (Id. ¶ 34). On April 4, 2022, Quest’s counsel sent Defendant a letter requesting the following: (i) provide an accounting for and identify all Quest Confidential Information in his possession; (ii) provide an accounting for and identify all Quest Confidential Information he transmitted to third parties; (iii) return all Quest Confidential Information in his possession; and (iv) allow a third-party IT vendor access to his personal email accounts, devices, and any cloud–based system to identify and delete all Quest Confidential Information. (Id. ¶ 35). The next day, Defendant confirmed that he received the letter, and further revealed that he had been working with Express Medical Labs since April 2021. (Id. ¶ 36). He ultimately agreed to respond to all inquiries by April 6, 2022. (Id.). On April 7, 2022, Defendant sent an email to Quest stating that he deleted the emails he sent to his personal email and that he did not transmit any Confidential Information to any third-party. (Id. ¶ 39). On April 14, 2022, Plaintiff filed the instant suit, alleging the following causes of action: (1) injunctive and equitable relief; (2) breach of contract; (3) breach of the implied covenant of good faith and fair dealing; (4) breach of the duty of loyalty; (5) misappropriation of trade secrets under the Defend Trade Secrets, Act, 18 U.S.C. §§ 1836, et seq.; and (6) misappropriation of trade secrets under the Nevada Uniform Trade Secrets Act, NRS §§ 600A, et seq. (Id. ¶¶ 44–88). Plaintiff simultaneously filed an Emergency Ex Parte Motion for Temporary Restraining Order. (Mot. Temporary Restraining Order, ECF No. 2), which this Court denied. Plaintiff then filed the instant Amended Motion for Preliminary Injunction, (ECF No. 12). The same legal standard applies to both temporary restraining orders and preliminary injunctions sought pursuant to Federal Rule of Civil Procedure 65. See Stuhlbarg Int’l Sales Co. v. John D. Brush & Co., 240 F.3d 832, 839 n.7 (9th Cir. 2001) (noting that the analysis applied to temporary restraining orders and preliminary injunctions is “substantially identical”). A preliminary injunction is “an extraordinary remedy that may only be awarded upon a clear showing that the plaintiff is entitled to such relief.” Winter v. Natural Res. Def. Council, Inc., 555 U.S. 7, 24 (2008). A court may grant such relief only upon a petitioner’s showing of (1) likelihood of success on the merits, (2) likelihood of irreparable harm in the absence of preliminary relief, (3) the balance of equities weighs in petitioner’s favor, and (4) an injunction is in the public interest. Id. at 20. A temporary restraining order is distinguished by its “underlying purpose of preserving the status quo and preventing irreparable harm just so long as is necessary to hold a hearing, and no longer.” Granny Goose Foods, Inc. v. Brotherhood of // Teamsters & Auto Truck Drivers Local No. 70,

Quest Diagnostics Incorporated v. Elarja, (D. Nev. 2022).

Quest Diagnostics Incorporated v. Elarja (Quest Diagnostics Incorporated v. Elarja) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related